Kynam Capital Management, LP Vertex Pharmaceuticals Inc Transaction History
Kynam Capital Management, LP
- $1.28 Billion
- Q2 2024
A detailed history of Kynam Capital Management, LP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Kynam Capital Management, LP holds 330,000 shares of VRTX stock, worth $155 Million. This represents 12.04% of its overall portfolio holdings.
Number of Shares
330,000Holding current value
$155 Million% of portfolio
12.04%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding VRTX
# of Institutions
1,718Shares Held
226MCall Options Held
1.21MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.7MShares$12.6 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.8 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.52 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.02 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $121B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...